Oncology Treatment Market

View All

ENHERTU: Another Triumph to Celebrate for AstraZeneca and Daiichi Sankyo

ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous sy...

Find More

Cancer Biomarkers: Improving Treatment and Detection

Cancer is the second leading cause of death worldwide, after ischemic heart disease. There are approximately 200 different types of cancer, with lung, prostate, colorectal, stomach, and liver cancer being the most common in men and breast, colorectal, lung, cervical, and thyroid cancer being the most common in wome...

Find More

Car-TCR Summit Europe 2020
Why should every company working on CAR-T therapy attend CAR TCR Summit Europe?

The third edition of CAR-TCR Summit Europe is a one-stop platform that provides attendees with a holistic view of the Gene therapy market, listing the solutions to the plausible hurdles that come across in the process. Hosting over 1000 industry-experts, the CAR TCR Summit is tailored for pharma & biotech play...

Find More